Matinas BioPharma Narrows Losses, Faces Going Concern Doubt

TL;DR

**MTNB is burning cash and explicitly warns it might not survive the next year without a miracle partnership or more dilutive financing.**

AI Summary

Matinas BioPharma Holdings, Inc. (MTNB) reported a net loss of $1.53 million for the three months ended September 30, 2025, a significant improvement from the $4.28 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $8.43 million, down from $15.82 million in 2024, primarily due to a substantial reduction in research and development expenses from $9.06 million to $85 thousand. General and administrative expenses also decreased from $7.07 million to $5.28 million for the nine-month period. The company's cash and cash equivalents stood at $5.44 million as of September 30, 2025, a decrease from $7.28 million at December 31, 2024. Total assets declined from $12.64 million to $9.70 million, while total liabilities decreased from $5.05 million to $3.24 million. The company issued 3,300 Series C Convertible preferred stock and warrants in a public offering, raising $3.30 million, and reclassified $6.10 million of warrants from liability to equity. Despite these efforts, the company explicitly stated that its cash and cash equivalents are not sufficient to fund planned operations beyond the next twelve months, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

Matinas BioPharma's significant reduction in R&D expenses and overall net loss signals a strategic shift towards cost control, which is critical for a clinical-stage biopharmaceutical company with limited cash. However, the explicit 'going concern' warning in the 10-Q is a red flag for investors, indicating a high risk of future dilution or even bankruptcy if new funding or partnerships for MAT2203 and its LNC platform are not secured. This financial precariousness could impact employee morale and job security, while customers and the broader market will be watching to see if their promising LNC platform technology can attract the necessary capital to advance its pipeline, especially in a competitive biotech landscape where funding is often tied to clinical progress.

Risk Assessment

Risk Level: high — The company explicitly states, "The Company does not believe the cash and cash equivalents on hand are sufficient to fund planned operations beyond the next twelve months from the filing date of these financial statements. As a result, substantial doubt exists about the Company's ability to continue as a going concern." This direct statement, coupled with an accumulated deficit of $208.88 million as of September 30, 2025, and continued net losses, indicates a very high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider selling MTNB shares due to the explicit 'going concern' warning and insufficient cash to fund operations beyond 12 months. Potential investors should avoid initiating a position until the company secures significant non-dilutive funding or a strategic partnership that resolves its liquidity issues.

Financial Highlights

debt To Equity

0.50

total Assets

$9.70M

total Debt

$3.24M

net Income

-$8.43M

cash Position

$5.44M

Key Numbers

• $8.43M — Net Loss (9 months) (Decreased from $15.82M in 2024, indicating improved financial performance but still a significant loss.)
• $5.44M — Cash and Cash Equivalents (Insufficient to fund operations beyond 12 months, raising going concern doubts.)
• $208.88M — Accumulated Deficit (Reflects historical losses, indicating a long path to profitability.)
• $85K — Research and Development Expenses (9 months) (Drastically reduced from $9.06M in 2024, showing a significant cutback in R&D activities.)
• $3.30M — Gross Proceeds from Private Placement (New capital raised through preferred stock and warrants, providing short-term liquidity.)
• $6.10M — Warrant Reclassification (Shifted from liability to equity, improving the balance sheet structure.)
• $1.53M — Net Loss (3 months) (Improved from $4.28M in the prior year quarter, showing quarterly loss reduction.)
• 6,406,191 — Common Shares Outstanding (As of November 6, 2025, indicating potential for further dilution given financing needs.)

Key Players & Entities

• Matinas BioPharma Holdings, Inc. (company) — registrant
• MAT2203 (company) — product candidate
• LNC platform (company) — delivery technology
• U.S. Food and Drug Administration (regulator) — regulatory body
• BTIG, LLC (company) — sales agreement partner
• $208,875 (dollar_amount) — accumulated deficit as of September 30, 2025
• $8,433 (dollar_amount) — net loss for the nine months ended September 30, 2025
• $5,435 (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $3,300 (dollar_amount) — gross proceeds from private placement of preferred stock and common stock warrants
• $6,103 (dollar_amount) — reclassification of warrants from liability to equity

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company explicitly states that its cash and cash equivalents of $5.44 million as of September 30, 2025, are not sufficient to fund planned operations beyond the next twelve months. This raises substantial doubt about its ability to continue as a going concern, despite recent capital raises and cost reductions.
• Significant Accumulated Deficit [high — financial]: Matinas BioPharma has an accumulated deficit of $208.88 million as of September 30, 2025. This reflects a history of net losses and indicates a long and challenging path to achieving profitability.
• Dependence on Future Financing [high — financial]: The company's stated inability to fund operations beyond 12 months necessitates future capital raises. With 6,406,191 common shares outstanding as of November 6, 2025, future financing efforts may lead to significant dilution for existing shareholders.
• Drastic R&D Expense Reduction [medium — operational]: Research and development expenses were cut from $9.06 million to $85 thousand for the nine months ended September 30, 2025. This substantial reduction signals a significant scaling back of R&D activities, potentially impacting future pipeline development.
• Declining Asset Base [medium — financial]: Total assets decreased from $12.64 million at December 31, 2024, to $9.70 million as of September 30, 2025. This decline, coupled with reduced cash reserves, indicates a shrinking operational footprint.

Industry Context

Matinas BioPharma operates in the highly competitive biotechnology sector, focusing on developing novel drug delivery platforms. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Companies often rely on substantial external financing to fund operations and clinical trials, facing intense competition from both established pharmaceutical giants and emerging biotech firms.

Regulatory Implications

As a biopharmaceutical company, Matinas BioPharma is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or issues with manufacturing processes can lead to significant setbacks and regulatory challenges. The company's financial condition also raises concerns about its ability to meet ongoing compliance and operational requirements.

What Investors Should Do

1. Monitor future financing activities closely.
2. Evaluate the strategic rationale behind the drastic R&D expense reduction.
3. Assess the impact of the Series C preferred stock issuance and warrant reclassification.
4. Scrutinize the company's cash burn rate and runway.

Key Dates

• 2025-09-30: Quarter End — Reported net loss of $1.53 million for the quarter, an improvement from $4.28 million in the prior year. Cash and cash equivalents stood at $5.44 million.
• 2025-09-30: Nine Months End — Reported net loss of $8.43 million, significantly down from $15.82 million in 2024, driven by R&D cost cuts. Total assets were $9.70 million, and total liabilities were $3.24 million.
• 2025-12-31: Prior Year End — Cash and cash equivalents were $7.28 million, total assets were $12.64 million, and total liabilities were $5.05 million.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability, standing at $208.88 million as of September 30, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The company explicitly states substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.)

Series C Convertible preferred stock

A class of preferred stock that can be converted into a predetermined number of common stock shares. (The company issued 3,300 shares in a public offering, raising $3.30 million, impacting its capital structure.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specific price within a certain timeframe. (The company reclassified $6.10 million of warrants from liability to equity, affecting its balance sheet presentation.)

Year-Over-Year Comparison

Compared to the prior year, Matinas BioPharma has significantly reduced its net loss for both the three-month period (from $4.28M to $1.53M) and the nine-month period (from $15.82M to $8.43M). This improvement is largely driven by a drastic reduction in R&D expenses, from $9.06M to $85K for the nine months. However, total assets have declined from $12.64M to $9.70M, and cash reserves have decreased from $7.28M to $5.44M, while the company explicitly warns of its inability to continue as a going concern beyond the next twelve months, a critical new risk.

Filing Documents

• form10-q.htm (10-Q) — 754KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 8KB
• form10q_001.jpg (GRAPHIC) — 18KB
• 0001493152-25-021506.txt ( ) — 4299KB
• mtnb-20250930.xsd (EX-101.SCH) — 33KB
• mtnb-20250930_cal.xml (EX-101.CAL) — 50KB
• mtnb-20250930_def.xml (EX-101.DEF) — 120KB
• mtnb-20250930_lab.xml (EX-101.LAB) — 323KB
• mtnb-20250930_pre.xml (EX-101.PRE) — 254KB
• form10-q_htm.xml (XML) — 535KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 3 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 16 Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 22 Item 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 22 PART - II OTHER INFORMATION 23 Item 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 23 Item 1A.

RISK FACTORS

RISK FACTORS 24 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 24 Item 3. DEFAULTS UPON SENIOR SECURITIES 24 Item 4. MINE SAFETY DISCLOSURES 24 Item 5. OTHER INFORMATION 24 Item 6. EXHIBITS 24 2 PART - I FINANCIAL INFORMATION Item 1. FINANCIAL STATEMENTS Matinas BioPharma Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands, except for share data) September 30, 2025 December 31, 2024 (Unaudited) (Audited) ASSETS: Current assets: Cash and cash equivalents $ 5,435 $ 7,284 Restricted cash – security deposit 50 50 Prepaid expenses and other current assets 168 691 Total current assets 5,653 8,025 Non-current assets: Leasehold improvements and equipment – net 156 468 Assets held for sale - net 70 — Operating lease right-of-use assets – net 1,351 1,680 Finance lease right-of-use assets – net 5 8 In-process research and development 2,260 2,260 Restricted cash – security deposit 200 200 Total non-current assets 4,042 4,616 Total assets $ 9,695 $ 12,641 LIABILITIES AND STOCKHOLDERS' EQUITY: Current liabilities: Accounts payable $ 80 $ 95 Accrued expenses 564 1,805 Operating lease liabilities – current 846 761 Financing lease liabilities – current 5 5 Total current liabilities 1,495 2,666 Non-current liabilities: Deferred tax liability 257 257 Operating lease liabilities – net of current portion 1,472 2,116 Financing lease liabilities – net of current portion 11 12 Total non-current liabilities 1,740 2,385 Total liabilities 3,235 5,051 Stockholders' equity: Series C Convertible preferred stock, stated value $ 1,000 per share, par value $ 0.001 per share, 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; 3,155 and 0 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. Liquidation preference of $ 3,155,000 as of September 30, 2025. — — Common

View Full Filing

View this 10-Q filing on SEC EDGAR